Alcami continues to strengthen its position as a trusted, end-to-end partner for pharmaceutical and biotech companies, building on its long-standing expertise in analytical development, formulation, and flexible drug product manufacturing. With a network that spans advanced analytical laboratories, GMP manufacturing suites, and robust stability infrastructure, Alcami has earned a reputation for scientific rigor, operational reliability, and the ability to support programs from early development through commercial readiness. Its integrated model allows clients to streamline workflows, reduce vendor complexity, and accelerate timelines, all of which have become increasingly important as companies navigate evolving regulatory expectations and supply-chain pressures.
This foundation is now further enhanced by Alcami’s acquisition of Tjoapack, a move that expands the company’s capabilities into specialized packaging, labelling, and serialization. Tjoapack’s three decades of packaging expertise integrate naturally with Alcami’s existing strengths, creating a more complete service offering that aligns with the needs of modern drug developers. The addition of primary and secondary packaging for oral solid dose and sterile injectable products allows Alcami to support clients across a greater portion of the product lifecycle, reducing handoffs and improving continuity between development, testing, manufacturing, and commercial supply.
Operationally, the integration of Tjoapack brings meaningful advantages. Packaging operations in Tennessee now connect directly with Alcami’s GMP storage facility in Garner, North Carolina, enabling efficient material flow and coordinated inventory management. The Wilmington, North Carolina site adds further resilience through secondary packaging and labelling capacity, giving clients built-in redundancy and reducing single-site dependency. These capabilities complement Alcami’s analytical laboratories in Morrisville, Durham, Wilmington, and St. Louis, allowing the company to internalize services that Tjoapack previously outsourced, including release testing, stability studies, and analytical development. The result is a more seamless, data-rich, and quality-controlled pathway from manufacturing to market.
For emerging biotechs and established pharmaceutical companies alike, Alcami’s expanded offering represents a stronger, more integrated solution. The company can now support products from early formulation through commercial packaging within a single, coordinated network, simplifying project management and enhancing supply continuity. At a broader level, the acquisition reinforces Alcami’s commitment to building a responsive, resilient life-sciences infrastructure in the United States. With Tjoapack now part of its network, Alcami is better positioned to meet the evolving needs of its customers, offering scientific excellence, operational strength, and supply-chain confidence through a unified, end-to-end service model.
